We provide innovative medical propellants to the world’s biggest pharmaceutical companies. All of our products are produced to the most demanding industry standards at our dedicated facilities. Find out more about our global community.
Zephex® 152a will reduce the carbon footprint by 90% compared to current metered dose inhalers. Our low GWP medical propellant is a commitment to both end users and our environment.
From the Newsroom
• New HFA 152a production facility will produce low global warming potential (GWP) propellants for pressurised metered dose inhalers (pMDIs). • The new propellant willRead more
- CPHI – Barcelona, Spain (24th and 26th October 2023)
- DDL – Edinburgh, Scotland (6th and 8th December 2023)